Brief: Rain Therapeutics Provides Interim Analysis Of Phase 2 Basket Trial Of Milademetan For MDM2-Amplified Advanced Solid Tumors
04/11/2022 12:03
Nov 4 (Reuters) - Rain Therapeutics Inc RAIN.O :
* RAIN THERAPEUTICS PROVIDES INTERIM ANALYSIS OF PHASE 2
BASKET
TRIAL OF MILADEMETAN FOR MDM2-AMPLIFIED ADVANCED SOLID TUMORS
(MANTRA-2)
* RAIN THERAPEUTICS INC - DRUG SAFETY PROFILE OF MILADEMETAN
PRELIMINARILY CONSISTENT WITH PRIOR PHASE 1 TRIAL
* RAIN THERAPEUTICS INC - PROTOCOL AMENDMENT PLANNED TO
ADJUST
MDM2 COPY NUMBER (CN) THRESHOLD TO CN ≥8 FROM CN ≥12; MANTRA-2
CONTINUES TO ENROLL
Source text for Eikon: ID:nGNX5kdYkw
Further company coverage: RAIN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million